Revolution Medicines, Inc.
RVMD
株式のランク
#579
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
株価
$196.16
時価総額
$42.04B
変化（1日）
7.69%
変化（1年）
263.19%
国
US
取引 Revolution Medicines, Inc. (RVMD)
カテゴリー
Healthcare
Revolution Medicines, Inc.（RVMD）のP/S比率
October 2026 時点のP/S比率 TTM: 0.00
Revolution Medicines, Inc. の最新の財務報告および株価によると、現在のP/S比率（TTM）は 0.00 です。2023 年末時点でのP/S比率は 280.24 でした。
Revolution Medicines, Inc. の P/S 比率の履歴（2017 ～ 2026）
各年末時点のP/S比率
| 年 | P/S比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 0.00 | -100.00% |
| 2023 | 280.24 | 416.25% |
| 2022 | 54.28 | -12.94% |
| 2021 | 62.35 | 1.65% |
| 2020 | 61.34 | 191.22% |
| 2019 | 21.06 | -59.70% |
| 2018 | 52.27 | 0.00% |
| 2017 | 0.00 | 0.00% |
同業他社のP/S比率
| 企業 | P/S比率 | P/S比率の差 | 国 |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
